Regeneron Pharmaceuticals (REGN) Posts Nearly Four Years Of Survival Benefit Data For Libtayo
Regeneron Pharmaceuticals (NasdaqGS: REGN) reported nearly four year Phase 3 C-POST data for Libtayo in high risk cutaneous squamous cell carcinoma. The C-POST trial showed sustained overall survival and disease free survival benefit for post surgery high risk CSCC patients. Investigators observed that Libtayo's survival benefit remained in place regardless of minimal residual disease status and despite high placebo crossover. Regeneron's story is broader than Libtayo's long term C POST survival data in high risk cutaneous squamous cell carcinoma. We have also spotted 2 other big wins worth knowing about at Regeneron Pharmaceuticals. For readers looking beyond one ticker and into a wider set of opportunities in this treatment area, consider exploring 34 healthcare AI stocks. Regeneron Pharmaceuticals, a US based biotech with a market value of about $80.4b, develops and manufactures…
